Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Amphivena Therapeutics , a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, today announced the first patient has been dosed in the Phase 1 dose expansion study evaluating AMV564, an investigational, first-in-class agent that

Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immunotherapeutics that restore anti-cancer immunity to the patient, today announced that Curtis Ruegg , Ph.D., President and CEO, will present a company overview at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020

The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.

Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, presented data on a novel assay for selection of acute myeloid leukemia patients for treatment with AMV564, at the 62nd Annual American Society of Hematology Meeting and Exposition, taking place virtually from December 5-8, 2020.